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ABSTRACT: 
In the past decade, stem cell therapy has been increasingly employed for the treatment of various diseases. 
Subsequently, there has been a great interest in the manufacture of stem cells under Good Manufacturing 
Practice (GMP), which is required by law for their use in humans.  
The Cells for Sight (CFS) Stem Cell Therapy Research Unit, based at UCL Institute of Ophthalmology, delivers 
somatic cell based and tissue-engineered therapies to patients suffering from blinding eye diseases at Moorfields 
Eye Hospital. The following manuscript is based on our experience in the conception, design, construction, 
validation and manufacturing within a GMP manufacturing facility based in the United Kingdom. As such the 
regulations can be extrapolated to the 28 member stated within the EU. However, the principles may have a 
broad relevance outside the EU. 
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AN INTRODUCTION TO REGULATIONS: 
Regenerative medicine (RM) has been defined as the ‘process of replacing, engineering or regenerating human 
cells, tissues or organs to restore or establish normal function’[1]. RM promises to revolutionize patient care in 
the 21st century through an amelioration of cell and tissue replacement therapies. Stem cell research plays a 
dominant role in RM through translational research aimed at repair and regeneration of diseased or ageing 
tissues and organs. A medicinal product, used for tissue regeneration within the European Union, must comply 
to the European regulations on the production of human[2] and veterinary[3] medicines and pharmaceuticals. 
Within Europe, the manufacture of medicines is regulated by European Medicines Agency, who decrees that 
each EU member state is required to elect a competent authority to oversee licensing of manufacturing facilities 
ratifying their compliance to Good Manufacturing Practices (GMP). GMP is a quality system for ensuring that 
medicinal products are manufactured consistently and to defined standards thus ensuring medicines are as safe 
as possible. GMP has historically been employed in the production of small molecules, proteins, vaccines and 
monoclonal antibodies [4]. However, in 2004, the European Commission ratified the Tissues and Cells Directive 
(EUTCD; [5]) which re-classified gene therapy, somatic cell therapies (which includes stem cell therapy 
products) and tissue engineered products as ATMPs (Advanced Therapy Medicinal Products) and imposed their 
manufacture (i.e. expansion or modification) to apply to the same GMP principals. Two Directives lay down the 
principals and guidelines of GMP for medicinal products, Directive 2003/94/EC which is concerned with 
medicinal products of human use [6] and 91/412/EEC intended for veterinary use medicines[7].  
One potential confusion within the field of cell therapy manufacturing is what regulations applies to human 
tissue and/or cells isolated from tissue used for direct transplantation or as part of a medicinal product. As 
previously mentioned, the EUTCD was issued in 2004 and one of its aims was to clarify these definitions. 
Where whole tissues intended for human application, are donated from the living or deceased, the consent, 
procurement, processing, testing, storage and disposal of that whole tissue is governed by EUTCD with UK 
enforcement provided by the Human Tissue Authority (HTA). Where individual cells, isolated from whole non-
embryonic human tissues, are expanded or modified to make a cell based medicinal product then their 
manufacturing and quality control testing, would fall under the ATMP Directive 2009/120/EC [8] and the 
regulating authority would be the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA 
are the competent authority within the UK, whose remit covers the regulation of medicines, devices, blood and 
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Advanced Therapy Medicinal Products (ATMPs) for human application. In the UK, manufacture of veterinary 
products is regulated by the Veterinary Medicines Directive (VMD). 
In addition to ensuring medicines are manufactured to GMP, the MHRA also issues authorisations allowing the 
distribution of safe and tested medicines on the market (termed a marketing authorisation; MA), or authorises 
their use within a clinical trial, the medicine in this case is termed an Investigational Medicinal Products (IMP). 
Facilities manufacturing medicines intended for release to the market must be granted a manufacturing license 
(MIA) by their competent authority, whilst facilities manufacturing IMPs must also obtain a separate MIA IMP 
license.   
In the UK, in addition to the above-mentioned manufacturing licenses (MIA or MIA IMP), ATMPs may be 
manufactured under a UK ‘Specials’ or a hospital exemption license for an unmet clinical need i.e. where no 
alternative licensed product is available.  Cells for Sight have experience of manufacturing ATMP ‘Specials’.  
Here, a bona fide, unsolicited request from the patient’s surgeon, in the form of a prescription, is required to 
commence the manufacturing process.  The legal responsibility for use of the ATMP in this case rests with the 
surgeon.  The main difference between the two types of licence are; that the holder of a ‘Specials’ license can 
manufacture an ATMP for any EU member, whereas a hospital exemption holder may only manufacture 
ATMPs for their own hospital’s patients. ATMPs manufactured as ‘Specials’ must meet the expectation of 
2003/94/EC [6] and Guidance Note 14 [9] and may be released by the Quality Controller (QC) of the 
manufacturing facility as opposed to the Qualified Person (QP).  
At CFS, we manufacture ATMP MIA-IMPs generated from expended stem cells to produce novel cell-based 
and tissue-engineered products. Medicinal products must be certified by a QP prior to release. The QP plays an 
integral role in medicine manufacture and must take final responsibility for the release of that product for human 
or animal use. The QP must ensure the product is safe by ratifying it has been manufactured to GMP and in 
accordance with the marketing authorisation (for products released to the market), or in accordance with an IMP 
Dossier (IMPD) and Product Specification File (for IMPs). 
Irrespective of the type of medicine being produced, and the type of license a manufacturing facility holds, the 
principles of GMP must always be applied in order to ensure medicines are consistently produced, of the highest 
quality, safe and effective for the end user. Under the EU regulations, ATMPs, which are classified as sterile 
medicinal products, must be manufactured within a cleanroom to ensure no contamination is transferred to the 
recipient. There are many requirements of a cleanroom in order for it to be ‘fit for purpose’ and the following 
section describes these in detail.   
 
CLEANROOMS: 
A cleanroom is a laboratory in which the level of particulate and microbial contamination is controlled.  
In Europe, Eudralex Volume 4 Annex 1 recognizes four clean room grades based on the maximum permitted 
number of particles per m3 and microbiological load limits [10]. These are listed in Table 1: 
 
Practically, the grades are distinguished as (Table 2): 
The environmental conditions within the cleanroom are controlled by a sophisticated Heating Ventilation and 
Air Conditioning (HVAC) unit, which controls the temperature, humidity, differential pressures between rooms 
and particulate content of the air. Clean air within the manufacturing facility is generated by a series of High 
Efficiency Particulate Air (HEPA) filters that deliver pressurised air, via a dedicated air-handling unit, to each 
room. Air is filtered through a series of pre-filters, panel filters and a terminal HEPA which is classified by its 
efficiency to remove its most penetrating particle size. At CFS the terminal HEPA is classified as H14 which 
means it removes 99.995% of particulates 0.1-0.3µm [11]. A pressure differential of 10-15 Pa between 
successive rooms creates a clean air cascade, which ensures that the air grade of each room is maintained. This 
pressure differential also ensures that particles within each room are carried outward with the outward flow of 
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air. Where microbial cross contamination is not a concern, the air can be recirculated; however, due to pressure 
drops through natural seepage, supplementation by filtered fresh air supplied from an AHU (Air Handling Unit) 
is required.  The air exhausted from the cleanroom is returned to the AHU (or in the case of single pass systems 
vented to the outside). The exhaust may also be HEPA vented depending on the type of material (e.g. viruses or 
GMOs) being manufactured.  
Generally, the airflow within the cleanroom is either turbulent or laminar. Laminar is uni-directional and 
involves a continual downward constant stream of air. Most cleanrooms are built with this design, however, 
some are turbulent flow which is not uni-directional and this method is used to move particles around the 
facility until it ultimately drives them to the floor and towards the extracts.  Turbulent flow cleanrooms are 
allowed for cell therapies when manufacture is performed under a laminar flow cabinet or bench. 
Where protection of the product is required, such as the cell therapy products manufactured at CFS there must 
be a positive pressure air gradient, whereby the air moves outwards from the Grade A/B laboratory in order to 
minimize environmental contamination of the product. For gene therapy products, or those containing high 
potency drugs, the primary processing Grade A/B laboratory is maintained under negative pressure surrounded 
by positive pressure gradients; for containment purposes. This is usually done through an air sink outside the 
processing room. 
 
CONSTRUCTION OF THE GMP FACILITY 
From a regulatory point of view, premises must be designed, constructed, located and maintained to suit the 
operations to be carried out. Materials used to line the floor and walls should be impervious to liquids and not 
release particles. Tiles should be avoided as gaps between tiles allow space for contamination to settle within 
and are also hard to clean. Internal surfaces should smooth and suitable for cleaning. The AHU should be 
situated outside the GMP facility so as to minimise the chance of contamination during its servicing and 
maintenance. Overall, the facility should be ergonomically designed to minimise the likelihood of operator error 
whilst allowing room for effective cleaning and maintenance so as to avoid build-up of particulates and cross- 
contamination that could adversely affect product quality. 
Once the facility is structurally built, the internal environment must be established. For cell therapy facilities, 
HEPA filters are usually installed in the ceiling with an extract near the floor which ensures that the majority of 
the facility is always exposed to airflow.  Pre-filters are generally installed in order to reduce the particle load on 
the HEPA filters. Pre and HEPA filters should be regularly serviced and checked to ensure that no particulate 
matter makes its way to the cleanroom facility. For optimum performance, pre and HEPA filters should be 
changed as per the manufacturer’s instructions. Lifespan of these filters pre-dominantly depends on the 
surrounding environment for eg. filters in an urban area might get dirtier compared to filters installed in a 
facility based in a rural landscape.  
Typically, the preferred method for entry/ exit within the cleanroom is the one-way flow of personnel, 
consumables and waste as it prevents room re-entry, therefore, minimising the risk of cross-contamination. Exit 
occurs through a separate de-gowning room. However, this setup is not always possible; therefore, backtracking 
through the previous rooms is allowed, albeit with extra precaution. Pass through chambers are generally built 
within the walls to allow for transfer of consumables, reagents and waste through the facility. Both the product 
and the waste can be transferred through the pass through chambers; however, they should be physically 
segregated. 
 
QUALIFICATION PROCESSES IN THE VALIDATION OF A CLEANROOM:   
Cleanrooms have to be validated and undergo a process of qualifications (Fig. 1). Only once it has passed all 
these requirements, can it be licensed for use in the manufacture of ATMPs destined for human application. 
EQUIPMENT: 
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Only equipment necessary to manufacture the medicinal product should be installed within the facility. At the 
outset, equipment should be validated, either by the supplier or the manufacturing team, to ensure it is fit for 
purpose and does not compromise product quality. The equipment should be placed in such a way that it does 
not obstruct the airflow within the facility. Post installation, all equipment must be serviced and calibrated as 
necessary to ensure that the quality of products is not compromised. Details of equipment specification, 
performance criteria, servicing and calibration must be retained for future reference. 
 
PERSONNEL: 
Of importance to every GMP facility are the Personnel who physically manufacture the product as per written 
procedures. Therefore, it is essential that there are sufficient personnel available to carry out all the tasks 
required for manufacture of the product. All personnel should be aware of and trained to their specific tasks. 
Training records for each individual should be generated and filed. Competence for all GMP related tasks 
including cleaning, gowning, aseptic technique etc should be documented on the training record.  
Each facility should have an organisational chart in which the responsibilities and the relationships between 
each individual are explicitly defined. Most GMP facilities are divided into two departments: Production and 
Quality Control/ Assurance; each as independent from the other as possible [12]. The production team is trained 
in and is responsible for all aspects of manufacturing the product. The QC department does not get involved in 
processing operations but does monitor and review the Quality Management System (QMS), approve starting 
materials, ensure testing and validations are carried out and reviews product related documentation/ 
investigations. The QC department may have a Quality Assurance (QA) unit which may perform all, or specific, 
aspects of the above dependent upon the companies’ organisation. In smaller facilities, both the QC and QA 
responsibilities maybe managed by the same individual.  
 
FACILITY MONITORING: 
The facility and equipment should be regularly monitored to ensure that there is minimal risk to the product 
quality. Ideally, an automated system should be installed to ensure continuous monitoring of all parameters. 
This should be supplemented by manual monitoring to ensure that any fault within the automated system is 
promptly detected without any effect on the product quality. Various parameters need to be monitored to ensure 
that the facility and the equipment housed within are functioning within their set specifications, these include 
but are not limited to: room temperatures and humidity, room pressures, pressure differentials, particle levels 
within the facility and safety cabinets, temperature, CO2 and humidity of the incubators, temperature of the 
fridge/ freezers etc. Each parameter should be continuously monitored and should additionally be manually 
checked during working hours.  
Monitoring particle counts is extremely important as particles may serve as a vector for attachment of various 
micro-organisms which pose a risk of contamination to the product. Particles, by themselves, can also 
contaminate the product. Related to the particle counts are the pressure differentials as a positive pressure 
cascade ensures that particles are removed from the GMP facility in an outward fashion. Equipment parameters 
are important as they maintain the integrity of the product and/ or reagents. 
 
MAINTENANCE OF THE CLEANROOM 
Following the qualification process, cleanrooms must be maintained to ensure they are ‘fit for purpose’. This 
includes ensuring personnel are trained to cleanroom procedures and ensuring environmental monitoring and 
cleaning is routinely performed. 
 
Cleaning 
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A documented cleaning routine is used to minimise the risk of particulate or microbiological contamination of 
products resulting from airborne and surface contaminants. The effectiveness of the cleaning routine is 
determined by regular environmental monitoring according to a documented series of validated procedures. 
Cleaning includes all surfaces, equipment, consumables, doors, walls and floor. It should be performed by 
trained personnel and be thoroughly documented. 
At CFS, cleaning of the manufacturing facility is performed on an in-use basis, a weekly basis, a monthly basis 
and a quarterly basis. ‘Critical areas’, i.e. those directly involved in product processing are cleaned on an in-use 
basis. ‘General areas’, i.e. those not directly involved in production but which present a low risk of 
contamination to critical areas via transfer, are cleaned with sterile 70% IPA (Isopropyl Alcohol)  according to a 
weekly, monthly and quarterly schedule, with alternating Biocide A (bactericidal and fungicidal), B or C  
(bactericidal, fungicidal and sporicidal virucidal) cleans on a monthly basis. If environmental monitoring results 
indicate that additional measures are required then extra ad hoc cleaning with Biocide A, B or C is performed. 
Biocides must be alternated to avoid development of resistance within organisms. Deep cleaning e.g. on an 
annual basis or following a persistent contamination resistant to routine cleaning may be performed with vapour 
hydrogen peroxide. To minimise particles within the facility, cleaning reagents are sprayed onto sterile low 
particle shedding wipes and then the reagent is wiped onto the surface being cleaned using unidirectional 
overlapping strokes to ensure that the whole area is cleaned. Ceiling, walls and floors are cleaned with a mop 
head attached to a mop. Other facilities may use pre-impregnated wipes for surfaces and equipment, or other 
validated cleaning systems. IPA is allowed to evaporate over time while biocides are left in contact with 
surfaces for 5 minutes.   Some Biocides leaves residues, and for these a second clean with IPA is performed. 
Biocides may be corrosive by nature, therefore, care should be taken to ensure that the biocide does not dry out 
and leave behind any residue.  
Large facilities tend to use pre-impregnated wipes for surfaces and equipment. This is advisable for large 
facilities as it is more cost effective whereas in smaller facilities, the impregnated wipes may dry out if left 
opened for days, leading to waste of reagents and money. 
Environmental Monitoring (EM) 
To establish whether the cleaning protocols meet the required standards with respect to control of particulate 
and microbiological contamination within the production areas, routine environmental monitoring is performed 
according to documented procedures. This is performed both ‘in-use’ to determine the level of contamination 
present during production, and ‘at-rest’ on a weekly basis to determine the effectiveness of cleaning routines. 
EM utilises a number of agar plates to monitor bacterial and fungal contamination, at CFS, Tryptone soya agar 
(TSA) and Sabaroud dextrose agar (SDA) plates are utilised respectively for this purpose. The plates themselves 
are of two different types: Settle and contact (Fig.2).  Contact plates themselves are used either to perform 
contact monitoring or active air sampling.  
Settle plate monitoring is a direct method for evaluating the approximate number of microorganisms depositing 
on the agar surface in a set amount of time; from air within the cleanroom.  
Contact plate monitoring is a method of surface sampling performed in order to determine the number of 
microorganisms/ contamination on any surface within the cleanroom or upon the operator’s apparel. Contact 
plates normally have a raised media surface to allow for direct application to the test surface.  
The air circulating within the cleanroom is also monitored by an active air sampler which captures air through a 
high pressure inlet. The captured particles collide against the agar surface and settle on it.  
At CFS, EM plates are incubated at specified temperatures (35⁰C for bacteria and 22⁰C for fungi) for 3-5 days 
and checked for colony forming units (cfu) to determine the number of microbe bearing particles deposited onto 
the agar. Positive and negative controls are also prepared to ensure the accuracy of results. Results from ‘at rest’ 
and ‘in-use’ environmental monitoring are recorded in a spreadsheet in order to determine any contamination 
trends. This information is used to determine if there is a need for corrective and preventive action, according to 
whether action levels or alert levels have been reached. Action levels are indicative of unacceptable levels of 
microbiological contamination and require corrective and preventive action to be taken in accordance with 
6 
 
written procedures. Action levels are those defined in ‘Rules and Guidance for Pharmaceutical Manufacturers 
and Distributors 2007’ [13]. Alert levels are set at 50% less than action levels, for which no action is necessary. 
Rather, the problem area is noted, its cleaning detail is improved, and personnel performance is evaluated to 
determine whether re-training is necessary. 
 
TRAINING  
Personnel  
Personnel are also a significant source of contamination. Therefore, traffic of personnel, visitors and engineers is 
strictly controlled to minimise the risk of particulate and microbiological contaminants entering the 
manufacturing facility. Cleanroom entry, gowning and hygiene routines are implemented according to validated 
procedures, in which all users of the facility are trained. Visitors and engineers are given training appropriate to 
their task prior to entry within the cleanroom. 
All users of the facility are also required to adhere to some basic behavioural and personal disciplines in order to 
minimise particle shedding and potential contamination, these include: 
 Maintenance of a good level of personal hygiene, including showering regularly, keeping dandruff at 
bay and moisturizing dry skin to reduce skin shedding 
 No cosmetics, talcum powders, hair sprays, nail polish or similar materials 
 No jewellery or watches within the cleanroom 
 Controlled movements within the cleanroom, with no rushing and to refrain from any sudden/ jerky 
movements 
In terms of particle shedding, movement is perhaps the greatest factor as the number of particles shed is 
proportional to the level of activity performed, with 100,000 particles  ≥ 0.5µm/min shed while sitting, rising to 
1 million when moving and 5 million when walking [14]. Therefore, slow, controlled movements within the 
cleanroom facility are essential to minimise aberrant particles. 
Gowning: 
Outdoor clothing should not be brought into the facility beyond the Grade C/D changing room. For wearing 
within the Grade A/B areas, sterilised protective garments should be provided (Fig. 3). Personnel must be 
trained to change clothing in accordance with a gowning procedure in order to minimise particle shedding and 
potential contamination within the facility.  
At CFS, all garments are sterilised by gamma irradiation by a specialist laundering company and are delivered 
triple wrapped. Each garment is single use and is sent back to the laundering company to be cleaned and re-
sterilised a finite number of times after use. 
In order for an operator to perform any processing in the facility they need to have passed a gowning training 
test, this involves gowning in according to cleanroom techniques to enter the grade B laboratories. Gowning is 
followed by a series of microbial monitoring contact plates to assess levels of contamination on areas of 
gowning which may come into contact during the gowning process – gloves, forearm, forehead, chest, and 
stomach. If the plates have passed i.e. no CFU on the contact plates, the operator is allowed to process in the 
facility.  
Aseptic training 
All staff members who work in the manufacturing facility, including those involved in product manufacture are 
trained in aseptic technique on recruitment and at regular intervals thereafter.  
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At CFS, all operators are required to pass a training module to demonstrate aseptic technique within the 
biological safety cabinets (Grade A environment) – this involves a three day process of manipulating cell culture 
plates or flasks and liquid handling, transferring sterile tryptone soya and sabouraud dextrose broths (TSB and 
SDB, respectively) between wells on three separate days and the inoculation of further TSB and SDB for 
subsequent incubation for 3 – 5 days and analysis for turbidity. Additionally in-use monitoring is also performed 
assessing the working environment and the operators’ gloves for contamination. In order to pass this training 
module, all broths should be free from turbidity and monitoring plates should be below allowable limits (Table 
3). This training module is repeated every 6 months and results recorded in the operators training record. This 
procedure is specific to CFS, other facilities will need to simulate training appropriate to the processes to be 
performed within their respective facilities. 
 
QUALITY MANAGEMENT SYSTEMS (QMS) 
A Quality Management System (QMS) has the purpose of assuring product specification and quality through the 
control of inter-connected elements and to mitigate potential risks to the product.  
QMS is based upon International Organisation for Standardisation (ISO) 9001:2008, a set of standards 
originally developed in 1987 to maintain quality assurance in product manufacturing and service industries. The 
pharmaceutical industry has further developed these standards through the International Conference on 
Harmonisation (ICH), to produce a harmonised comprehensive model for an effective pharmaceutical quality 
system designed for the entire product lifecycle.  
Within the pharmaceutical industry, a QMS is the requirement of Directive 2003/94/EC (manufacture of 
medicinal products for human use); [6] and Directive 91/412/EEC (manufacture of medicinal products for 
veterinary use); [7], and ensures the principals and guidelines of these Directives are implemented, including 
compliance to GMP.  
All further reference to the QMS within this publication will be based on the CFS QMS, unless otherwise 
specified. The QMS defines how the activities performed during ATMP manufacture ensure compliance to local 
regulatory requirements of the MHRA and HTA. The CFS QMS is organised into the following categories: 
Validations; Donor Recruitment and Patient Treatment; Production and Quality Control; Quality Assurance, 
where each category comprises of a set of Standard Operating Procedures (SOP’s) that provide a top-level 
description of how the QMS is implemented (Fig. 4). 
Additional to the SOPs, various documented procedures (including Quality Assurance Forms, Training Forms, 
Corrective and Preventive Action Procedures, and Production Protocols) are used to execute the QMS for the 
manufacture of ATMPs.  
The following describes the requirements and the implementation of the various sections of the QMS and how it 
interacts with GMP compliance and human tissue regulations.  
Validations are required to be performed for a process, reagent, a piece of equipment or for the manufacturing 
facility itself in order to ensure the parameter in question is ‘fit for purpose’ and will not affect product quality 
once initiated or implemented. Following quality approval, successful validations allow the parameter in 
question to then be built into the QMS through updates to existing GMP documentation or implementation of 
new GMP procedures.   
A section of the QMS is dedicated to Donor Recruitment and Patient Treatment to ensure the CFS facility, when 
manufacturing ATMP’s using autologous or allogeneic donor tissue and cells, complies to the legal framework 
(Human Tissue Act 2004 [15], the Human Tissue Regulations 2007 [16] and EU Tissues and Cells Directives 
[5]) that dictates procedures surrounding consent for tissue donation, procurement, testing, storage, disposal and 
use of body parts, organs and tissue . 
The QMS also details policies around production and quality control activities. The Production SOP documents 
the required production procedures to be performed to maintain GMP standards. Such procedures include; 
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facility clean, facility and environmental monitoring, equipment planned preventative maintenance (PPM) and 
QC sterility assessments for aliquoted reagents. 
Quality Assurance (QA) is directly concerned with assuring the quality of a product through controls that are 
described in a set of SOPs. Quality Assurance is also concerned with monitoring procedures and processes, 
providing a feedback loop to aid improvements in order to prevent error in the future. Although each of the 
aspects detailed in Fig. 3 is essential to the smooth running of a cleanroom, only the critical sections will be 
discussed here. 
The investigation of deviations forms a major part of any organisation’s strategy for risk management and 
quality improvement. Where a deviation or non-conformance occurs within a prescribed process, the incident 
needs to be recorded and corrected. The term ‘deviation’ is used to include process deviations, planned changes, 
out of specification events and any other non-compliance with GMP. This overall system includes; recording of 
the deviation, assessment of the deviation in terms of risk to the facility, product or patient, root cause analysis, 
planning and implementation of Corrective and Preventative Actions (CAPA) and routine trending of deviations 
so that higher levels of preventative action can be taken. 
A complaint is defined as any defect in a product or service reported by either an external or internal customer. 
The Complaints and Recalls SOP defines the process employed which includes risk and impact assessment, root 
cause analysis and implementation of CAPA to prevent a similar issue occurring in the future.  
Change Control is the process that defines the way in which changes to all aspects of the QMS are managed. In 
practice the following require change control: starting materials, documents, equipment, processes, any change 
that has a regulatory impact e.g. key staff changes, new product types, facility changes and any other change 
that may affect the quality of the product. Changes can occur in response to many parameters for example; 
deviation, complaint, audit, introduction of a new project, or contract change. Change requests are trended and 
reviewed periodically to help identify potential improvements.  
A Service level Agreement (SLA) must be in place when an organisation provides a service to, or is provided 
with a service from, a third party. The SLA will establish the expectations and requirements that should be met 
by both parties. Should we define the different one? 
Before a medicinal product can be used to treat a patient, it must be formally released for use by CFS and 
therefore only officially released products can be used to treat a patient. The Batch Release SOP documents the 
procedures by which a product is released for patient use including; review of batch records, test results, 
deviation reports and monitoring results culminating in a formal sign-off by the QP for IMP products or the QA 
Manager for ‘specials’ products.  
The Materials Management SOP documents the controls in place to mitigate potential risks to the product due to 
materials used within GMP manufacture. The controls described within this SOP include the following; 
goods/supplier selection and risk assessment, TSE compliance assessment, goods ordering and receipt, 
traceability and stock rotation/storage/reconciliation. 
As previously described, all of the above factors have to be stringently controlled in order to ensure medicines 
(including cell therapy products) are manufactured safe, effective and of the highest quality. Below is an 
example of how a CFS product is manufactured in adherence with EU regulations and the CFS procedures 
described above. 
 
LIMBAL EPITHELIAL STEM CELLS AND LIMBAL STEM CELL DEFICIENCY: 
CFS have worked with academic, industry and NHS partners in the manufacture of cell therapy products. One 
particular cell based therapy manufactured by CFS is used to treat patients’ suffering from blinding eye diseases 
such as limbal stem cell deficiency (LSCD) which results in corneal degeneration. 
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The cornea is the clear, front surface of the eye that transmits light to the retina to enable vision. Corneal 
epithelium is separated from the conjunctival epithelium by a narrow band of tissue known as the limbal 
epithelium. Limbal epithelial stem cells (LESC) reside within the limbal epithelium and play a role in the 
maintenance and renewal of the corneal epithelium [17]. Dysfunction or damage of the limbal epithelium can 
lead to either unilateral or bilateral LSCD, which is characterized by vascularization, conjunctival ingrowth and 
inflammation resulting in visual impairment [18]. LSCD can be treated by replacement of the lost or damaged 
LESC by autologous or allogeneic transplantation of limbal tissue. CFS devised a technique utilizing a fully 
reproducible fibrin gel substrate for the culture of autologous or allogeneic limbal and autologous oral mucosal 
epithelial cells [19].  
Described below is a brief explanation of the production of a GMP compliant cell therapy graft within CFS.  
 
GRAFT PREPARATION: 
As previously described, the implementation of any process within the cleanroom requires validation. At CFS, 
the graft production process was conceptualized and optimised in the research lab before finally, performing a 
process validation within the cleanroom facility. The process of graft production within the cleanroom is 
described below. The flow of the production process can be observed in Figure 5. 
Prescription and Patient selection criteria 
The process is initiated when the CFS team receives a prescription from the clinician requesting a specific 
‘Specials’ product. The clinician obtains patient consent, and with them completes donor selection and testing 
forms which include lifestyle and medical questionnaires and also includes testing at minimum for HIV 1 and 2, 
hepatitis B and C and Syphilis [20]. There is generally no difference in virology testing between autologous or 
allogeneic donors so as to ensure that tissue coming into the cleanroom facility is identically screened. An 
exception would occur where patients have travelled to ‘at-risk’ countries or where the behaviour and lifestyle 
questionnaire indicates further testing maybe required as per the guidelines.  The results of a blood sample for 
serological screening may be obtained in sufficient time, prior to tissue donation, to allow assessment of 
infection risk to the GMP facility.  In the UK, a second blood sample for serological screening should be 
obtained on the day of tissue donation (or within 7 days post donation if the former is not possible) in 
accordance with HTA Direction 003/2010 [21]. 
Cell culture media 
As there is no universally accepted list of suitable materials and reagents for the manufacture of ATMPs, each 
facility must perform a risk assessment (RA) to ensure that the components used pose the least risk to the 
patient. RA addresses various criteria including tests for viruses, bacteria, fungi, mycoplasma and endotoxins to 
justify the use of the product. Currently available cell culture reagents are mostly approved for research use 
only. Therefore, the RA must demonstrate why the reagents in cell culture media are justified for use, as per the 
regulations. Manufacturers should provide all quality certificate available (i.e. Certificates of Analysis, Origin 
and TSE/ BSE compliance) upon which, these assessments will be made.  
Cell culture process 
Cell culture media for clinical grafts were prepared on a weekly basis to avoid any contamination during the cell 
culture process. Therefore, all the media components need to be aliquoted and pass QC prior to the start of cell 
culture. Once all the media components have passed their sterility testing, a limbal biopsy (autologous or 
allogeneic) or an autologous oral mucosal biopsy, as determined by the consulting clinician, may be accepted to 
commence cell therapy manufacture.  
In the past, CFS manufactured epithelial cell grafts for patients using human amniotic membrane as described in 
[22]. However, due to batch-to-batch variability in amnion [23], CFS developed an alternative technique 
utilizing a CE marked fibrin substrate for culture of epithelial cells [19]. This technique is currently being used 
by CFS for manufacture of epithelial cell grafts for ocular surface reconstruction.  
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The tissue culture process is set up as previously described in. The cells are fed with freshly prepared media 
every 2 days. Cell morphology, percentage of confluence and media turbidity are recorded at every feeding 
session. 
Critical Quality Parameters 
To release the epithelial cell graft, critical quality parameters must be met. These include but are not limited to 
adherent and healthy epithelial cells with cobblestone morphology, integrity of the fibrin gel, no contamination. 
The graft is released for transplantation only if all of the above criteria are met. The release is authorized by the 
QA manager who reviews all of the batch records and associated testing results. 
Packaging the graft 
The cell culture media on the graft is replaced by transport media, in our case L-15, which supports the cells in 
environments without CO2 supplementation, the culture plate has an adhesive primary label attached to it and 
the graft is packaged in a clinical pouch sealed with GMP compliant tape. The plate is then placed into a 
labelled transport box. The labels and the pouch are marked with details of the patient, the cell therapy product 
type, expiry date and expiry time of the graft and facility contact details. Upon completion of the batch release 
process, the graft is delivered to the hospital for transplantation onto the patient’s eye. Upon exchange of the 
graft to hospital personnel a ‘chain of custody’ form is completed to document the final stage in the process 
where the graft becomes the clinical teams’ responsibility from this point.  
Post release sterility data 
The final media sterility data is only available post transplantation. In the event of a positive result, the hospital 
and the MHRA should be alerted, as per their guidelines. The microorganism would be identified and the 
species communicated to the clinical team who would treat the patient as per the clinicians’ directive. 
Patient related data storage 
All documentation should be securely stored for the period of time defined by the directives under which the 
work is being performed.  
 
FUTURE PERSPECTIVES:  
Stem cell research has the potential to deliver a host of new cell therapies. The European Medicines Agency has 
recently granted marketing authorization to the first ever commercial stem cell therapy to treat LSCD. With 
increasing research progressing towards clinical trials, there is an ever increasing need for an understanding of 
the regulations in the production of cell therapies. Due to the vast range of possible cell therapies, it is difficult 
for regulators to provide guidance on specific developments within the field. Reviews like this are likely to be 
beneficial for future manufacturing facilities and users as they would bridge the gap between understanding and 
implementing the various regulations and guidelines involved in the manufacture of cell therapies. This review 
is also beneficial for researchers planning ATMP manufacture or clinical trials to understand the additional 
requirements in transferring the cell culture process from the research laboratory to the GMP facility.  
 
EXECUTIVE SUMMARY: 
Regulatory Requirements within the United Kingdom 
 For manufacturing cell therapies, compliance to various legislations announced by the European Medicines 
Agency is required. The most important directives describing the manufacture of cell-based medicinal 
products for human use are Directive 2001/83/EC, Directive 2004/23/EC and 2003/94/EC. 
 Where whole tissues intended for human application, are donated from the living or deceased, the consent, 
procurement, processing, testing, storage and disposal of that whole tissue is governed by EUTCD with UK 
enforcement provided by the Human Tissue Authority (HTA). 
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 Where individual cells, isolated from whole non-embryonic human tissues, are expanded or modified to 
make a cell based medicinal product then their manufacturing and quality control testing, would fall under 
the ATMP Directive 2009/120/EC and the regulating authority would be the Medicines and Healthcare 
products Regulatory Agency (MHRA). 
  
GMP facility construction and maintenance 
 The GMP facility should be constructed in a way that it is easy to maintain. The materials used in the 
construction should be low particle shedding and not allow space for contamination/ dust to collect i.e. be 
easily accessible to allow for cleaning to occur. 
 Cleaning processes should be validated and performed accordingly. The cleanroom should be periodically 
monitored to ensure that the cleaning protocols are effective and that the environment possesses no risk to 
the product quality. 
 Well qualified and trained staff should be employed to reduce the occurrence of errors 
  
Quality Management System 
 All licensed manufacturing facilities should have a Quality Management System (QMS) which defines how 
the requirements of the specific regulatory agencies are enforced to ensure that cell therapy production is 
within the required legislation. A QMS will typically include policies around GMP non-compliance 
reporting, validations, materials management, quality assurance procedures, complaint reporting and change 
control to name but a few. 
  
       Cell therapies for limbal stem cell deficiency (LSCD) 
 CFS, as a licensed facility, delivers cell based therapies to patients suffering from blinding eye diseases 
such as limbal stem cell deficiency ensuring compliance to all of the above. Limbal stem cell deficiency 
occurs when the cornea, the front surface of the eye, degenerates due to the dysfunction of the limbal stem 
cell population. CFS have developed an LSCD therapy consisting of epithelial cells in combination with a 
novel fibrin gel substrate. The manufacturing process includes stringent procedures and controls in order to 
ensure the end product is both consistent and of the highest quality. 
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FIGURES: 
 
Figure 1: Validation of the cleanroom. Validation of the cleanroom will include a user requirement specification (URS) which is a high 
level requirement and expectations for systems to be used as the basis of testing during the Performance and/or Operational Qualification 
(PQ/OQ) phases. The URS leads to a design qualification (DQ) which is a document that defines all hardware and software components to 
be installed and the configuration management plan needed to meet the URS and/or owned project requirements. This in turn would lead to 
an installation qualification (IQ) which is the documented verification that all aspects of the system that can affect product quality adhere to 
approved specifications and are correctly installed. Commissioning of the area follows the IQ operating qualification and is a well-planned 
and documented systematic challenge and verification using inspection, testing and documentation that a facility, system and/or piece of 
equipment is constructed, installed, started and functionally operates together, through normal modes and conditions in accordance with 
design and installation requirements and acceptance criteria. After commissioning, the operating qualification (OQ) follows which is the 
documented verification that all aspects of the system that can affect product quality operate as intended throughout all anticipated and 
tested ranges. Finally the performance qualification (PQ) is performed which is the documented verification that all aspects of the system 
that can affect product quality repeatedly and consistently perform as intended, meeting pre-determined acceptance criteria.  
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Figure 2: Examples of a contact and settle plate for environmental monitoring. At CFS, both plates are filled with either tryptone soya 
agar, or Sabouraud agar depending on the requirements of the monitoring. The agar also contacts various chemical neutralisers to inhibit the 
action of biocides to prevent false negatives. The contact plates have a raised agar surface to allow monitoring of surfaces without the side 
of the dish preventing contact being made (such as cabinet surfaces or glove prints form operators) whereas the settle plates are used for 
passive monitoring of the air within the cleanroom. Additionally the contact plates are used in conjunction with an active air sampler to 
actively monitor air contamination when required. 
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Figure 3: Garments required to operate / process at or above grade B. Operators are required to remove outdoor shoes and clothes and 
change into cleanroom tunics, trousers and clogs, and the donning of gloves and a mobcap (not shown above) prior to entering the facility. A 
second level of gowning is then performed prior to the operator moving to the Grade B laboratories, this involves putting on fresh gloves, a 
hood, safety glasses, a face mask, coverall and overboots, all of these items will have been sterilised by irradiation.  
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Figure 4: The CFS Quality Management System. The CFS QMS is divided into Validations, donor recruitment and patient treatments, 
production and quality control and quality assurance.  
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Figure 5: Process flow for the production of cultured epithelial cell grafts at CFS. The process flow diagram illustrates the steps 
involved in the production of cultured epithelial cell grafts at CFS. It encompasses all the quality, production and clinical requirements 
essential in the production of a GMP compliant cell therapy graft.  
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TABLE LEGENDS 
Table1: Cleanroom classification based on the maximum number of permitted particles/ m3. The classification of cleanrooms includes 
maximum particles per metre cubed of the 0.5 micron and the 5.0 micron particles.  Usually there are two sets of levels allowed, one is for 
in-process and one is for at-rest [24].   
Table2: Practical application of the different air grades of the cleanroom. The different air grades within the cleanroom are suitable for 
performing different processes. Each processing operation should be carefully planned based on the grade it will be performed in [24]. 
Table3: Recommended limits for microbial contamination. The classification of cleanrooms includes maximum CFU (Colony forming 
unit).  Usually there are two sets of levels allowed, one is for in-process and one is for at-rest [24].   
 
 
 
 
 
ABBREVIATIONS: 
GMP Good Manufacturing Practice 
CFS Cells For Sight 
UCL University College London 
RM Regenerative Medicine 
EUTCD European Union Tissue and Cells Directive 
MHRA Medicines Healthcare and Regulatory products 
Agency 
ATMP Advanced Therapy Medicinal Products 
HTA Human Tissue Authority 
VMD Veterinary Medicines Directive 
MA Marketing Authorization 
IMP Investigative Medicinal Products 
QC Quality Control 
QP Qualified Person 
IMPD Investigative Medicinal Products Dossier 
HVAC Heating, Ventilation and Air Conditioning 
HEPA High Efficiency Particulate Air 
AHU Air handling Unit 
QA Quality Assurance 
QMS Quality Management System 
IPA IsoPropyl Alcohol 
TSA Tryptone Soya Agar 
SDA Sabaroud Dextrose Agar 
EM Environmental Monitoring 
CFU Colony Forming Unit 
TSB Tryptone Soya Broth 
SDB Sabaroud Dextrose Broth 
ISO International Organisation for Standardisation 
ICH International Conference on Harmonisation 
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PPM Planned Preventative Maintenance 
CAPA Corrective And Preventative Actions 
SOP Standard Operating Procedure 
SLA Service Level Agreement 
TSE Transmissible Spongiform Encephalopathy 
LSCD Limbal Stem Cell Deficieny  
LEC Limbal Epithelial Cells 
HIV Human Immunodeficiency Virus 
 
